Latest Regulatory Filings News

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

North Stawell Minerals has completed a $1 million placement, issuing over 33 million shares to fund its exploration efforts in Victoria's Stawell Mineralised Corridor.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Findi Limited has appointed DAM Capital and Ambit as lead managers for the IPO of its Indian subsidiary, Transaction Solutions International, targeting a valuation near A$900 million and a 2026 listing.

Brookside Energy has expanded its SWISH Play acreage in Oklahoma's Anadarko Basin by adding a fifth Drilling Spacing Unit, increasing its high-impact drilling inventory by over a quarter. This move strengthens its development pipeline ahead of a planned NYSE listing.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Shift4 Payments, LLC has entered into a definitive scheme implementation agreement to acquire Smartpay Holdings Limited at NZ$1.20 per share, subject to regulatory and shareholder approvals. The transaction outlines a detailed timetable and conditions, including Overseas Investment Office consent and court sanction.

North Stawell Minerals Ltd (ASX – NSM) has opened a $2.1 million non-renounceable entitlement offer to fund key gold exploration projects in Victoria. This follows a $1.5 million placement, together raising $3.6 million to advance drilling and development.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

CLINUVEL’s Phase II pilot study reveals afamelanotide monotherapy does not trigger repigmentation in vitiligo patients, underscoring the necessity of adjunct NB-UVB phototherapy.

Coronado Global Resources has finalised a US$150 million secured lending facility to bolster its liquidity, supporting ongoing expansion and cost-saving efforts amid a tough coal market.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.